Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      EMEA/Our innovation /Focus areas/Oncology /Lung cancer

      Lung cancer

      In 2020, lung cancer was the leading cause of cancer deaths in Europe, and was associated with 384,000 deaths. [1]

      At Johnson & Johnson Innovative Medicine Oncology EMEA, we are precisely focused on mastering the areas where we can make the most meaningful difference. We are dedicated to developing targeted, innovative therapies for lung cancer that transform outcomes, improving patients’ quality of life and increasing survival rates.
      lung_banner.jpg
      At Johnson & Johnson we’re concentrating on developing targeted therapies for patients whose treatment options are limited and who tend to have poor outcomes. Specifically, we are working on addressing the need for targeted therapies that address specific subtypes of lung cancer, particularly for people with non-small cell lung cancer (NSCLC), one of the world’s most common and deadly cancers.[1][2][3]
      Expand
      The five-year NSCLC survival rate is 24%[3] and targeted therapies can help people with NSCLC live longer, with a better quality of life.[4] NSCLC can be driven by a range of different mutations, with different characteristics.[5] The EGFR (epidermal growth factor receptor) gene is one of those affected by these mutations.[2][6]

      EGFR exon 20 insertion mutations are a specific subtype of EGFR mutation. These mutations are an uncommon form of EGFR-mutated NSCLC, and are known to be associated with poor survival outcomes.[7]

      More effective, targeted, and tolerable therapies for patients with EGFR exon 20 insertion mutations are urgently required, as treatment options are generally limited to chemotherapy. [8][9][10]
      Collapse
      An overview of Exon 20 insertion mutations
      An overview of Exon 20 insertion mutations
      An overview of Exon 20 insertion mutations
      Not only is lung cancer the leading cause of cancer death, but it also carries a high symptom burden with associated lowered quality of life. At Janssen, we are committed to developing innovative targeted therapies that address the unmet needs for specific types of lung cancer hoping to improve patients’ quality of life and survival rates.”
      Martin Vogel
      EMEA, THERAPEUTIC AREA LEAD ONCOLOGY, JANSSEN EUROPE, MIDDLES EAST & AFRICA
      We collaborate to innovate

      Underpinned by the scale and success of Johnson & Johnson, J&J Oncology is a growing force in oncology. Nevertheless, we know that change can only come through collaboration. We invest our time, expertise and resources and partner with experts to unlock the potential around us, all in pursuit of better outcomes for patients and their families.

      Johnson & Johnson is uniquely positioned as a company that spans the entire spectrum of human health: medical devices, pharmaceuticals, and consumer products. As the most broadly-based healthcare company in the world, we partner with external companies across all parts of our business.

      One such partnership scheme is our Lung Cancer Initiative (LCI), which aims to improve outcomes in lung cancer for patients in Europe and beyond. By developing partnerships and innovation, we can address the current challenges that face lung cancer patients across the world.

      The initiative is being expanded to the EMEA region, with the same goal of finding better ways to screen, prevent and intercept lung cancer. We’ll be providing further information on our progress in EMEA soon.
      More from Oncology at Johnson & Johnson Innovative Medicine EMEA
      Multiple myeloma
      June 6, 2024
      Read more
      B-cell malignancies
      June 6, 2024
      Read more
      Prostate cancer
      June 6, 2024
      Read more
      Bladder cancer
      June 6, 2024
      Read more

      References

      [1] IARC. Online analysis table. Available at: https://gco.iarc.fr/today/onlineanalysis-table?v=2020&mode=cancer&mode_p.... Last accessed October 2022.
      [2] Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016 Jun;5(3):288-300. doi: 10.21037/tlcr.2016.06.07.
      [3] Cancer.Net. Lung Cancer - Non-Small Cell: Statistics. Available: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. Last accessed October 2022
      [4] Dong J, Li B, Lin D, Zhou Q and Huang D. Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing. Front. Pharmacol. 2019; 10:230. doi: 10.3389/fphar.2019.00230.
      [5] Vyse, S., Huang, P.H. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Sig Transduct Target Ther 4, 5 (2019). https://doi.org/10.1038/s41392-019-0038-9.
      [6] Li Y, Appius A, Pattipaka T, Feyereislova A, Cassidy A, Ganti AK. Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA. PLoS One. 2019 Jan 4;14(1):e0209709. doi: 10.1371/journal.pone.0209709.
      [7] Oxnard GR, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18.
      [8] Masood A, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib. Semin Oncol. 2019;46(3):271-283.
      [9] Crossland V et al. HSR19-082: Epidemiological Findings and Outcomes in Non-Small Cell Lung Cancer Patients with Exon 20 Insertion Mutations: A Meta-Analysis. JNCCN 2019; 17(3.5).
      [10] DerSarkissian M et al. HSR19-084: Real-World Treatment Patterns and Clinical Outcomes in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations. JNCCN 2019; 17(3.5).
      [11] Carioli G, et al. European cancer mortality predictions for the year 2020 with a focus on prostate cancer. Ann Oncol. 2020 May;31(5):650-658.
      [12] Data on file_Medscape activity and JMC content_Annual global prevalence of EGFR ex20ins, 2020.
      [13] Bray F et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394–424.
      [14] Zhang Y et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 2016; 7(48): 78985–78993.
      [15] Yasuda H et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med 2013; 5(216): 216ra177.
      [16] WebMD. What Is B-Cell Lymphoma: Available at: https://www.webmd.com/cancer/lymphoma/what-is-b-cell-lymphoma#1. Last accessed October 2022.
      [17] Iyer RK, Bowles PA, Kim H, Dulgar-Tulloch A. Industrializing autologous adoptive immunotherapies: manufacturing advances and challenges. Front Med (Lausanne). 2018;5:150.
      [18] HEAL. Men Prostate cancer. Available at https://www.envhealth.org/IMG/pdf/prostate_testical.pdf. Last accessed October 2022.
      [19] European Cancer Patient Coalition White Paper on Bladder Cancer 2016. Available at: https://ecpc.org/wp-content/uploads/2019/08/ECPC-White-Paper-Bladder-Cancer-EN-1.pdf - Last accessed October 2022.

      CP-459038
      September 2024